IndustryCompany release

Alnylam third-quarter net product revenue reaches $1.29bn as TRITON-CM enrolment target rises

🇺🇸 Alnylam Pharmaceuticals, Inc. (ALNY) · Thu 29 Oct 2026

Alnylam reports $1,292m in global net product revenue for Q3 2026, widens its Phase 3 nucresiran study in ATTR-CM and flags a pivotal Huntington's programme for 2027.

Alnylam Pharmaceuticals reported its third-quarter 2026 results on 29 October, posting global net product revenue of $1,292 million. The company's headline described this as a 52% rise.

The TTR franchise drove most of the total. AMVUTTRA and ONPATTRO together generated $1,150 million in the quarter, according to the company.

Alnylam also raised the target enrolment for TRITON-CM, its Phase 3 study of nucresiran in transthyretin amyloid cardiomyopathy (ATTR-CM), to about 2,250 patients. The company says its expected launch timing for the product remains 2030.

In neurology, Alnylam reported positive Phase 1 data for brezosiran in Huntington's disease. It plans to start a pivotal study in 2027, subject to alignment with regulators. The summary available does not give details of the Phase 1 results or the regulatory discussions.

What it means for your team

  • Regulatory teams tracking nucresiran should note the larger TRITON-CM population while the company holds to a launch expected by 2030.
  • Brezosiran's pivotal plans depend on regulatory alignment, so any agency feedback on trial design in Huntington's disease will be a milestone to watch.
  • Market-access teams in ATTR-CM should note the commercial weight of AMVUTTRA and ONPATTRO, which made up most of Alnylam's Q3 net product revenue.

Company's press release (SEC filing): Alnylam Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Alnylam Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →